Table 1.
Baseline characteristics
| Parameter | Value |
|---|---|
| Safety population, patients (all treated) | 51 |
| Age at study entry (y), median (min-max) | 56 (35-82) |
| Male, n (%) | 31 (61%) |
| Splenomegaly (length >12 cm on sonograph), patients (%) | 31 (61%) |
| Spleen length on sonograph, median in cm (min-max) | 13.1 (8.0-22.0) |
| Patients with phlebotomies in 3 mo before screening, n (%) | 31 (61%) |
| Number of phlebotomies in 3 mo before screening, median (range) | 2 (1-8) |
| PV history before entry (mo), median (Q1-Q3) | 17.0 (3.6-68.8) |
| Major cardiovascular events in the med history, patients (%) | 11 (22%) |
| HU pretreated, patients (%) | 17 (33%) |
| Hct, %, median (min-max) | 44.8 (36.9-53.8) |
| Platelets, G/L, median (min-max) | 429 (148-1016) |
| WBC, G/L, median (min-max) | 11.1 (4.7-30.9) |
| JAK2 V617F–positive | 100% |
| %V617F allelic burden, median (min-max) | 41% (2-100) |
Hct, hematocrit; WBC, white blood cells.